Parker & Waichman, LLP Attorneys at Law CRESTOR Information Guide
|
|
- Neal Eaton
- 5 years ago
- Views:
Transcription
1 Parker & Waichman, LLP Attorneys at Law CRESTOR Information Guide The Case Against CRESTOR: Kidney Problems & Rhabdomyolysis Crestor has been linked to serious side effects including: kidney damage, kidney failure and rhabdomyolysis. On October 22, 2004, the consumer group Public Citizen said twenty-nine patients who took AstraZeneca's cholesterol drug Crestor developed kidney damage. Manufacturer: Astra Zeneca Generic Name: Rosuvastatin Date Approved: August 8, 2003 Status: On the market Approved Uses: Cholesterol Serious Side Effects: Kidney damage Kidney failure Muscle damage Rhabdomyolysis Related Topics Baycol Rhabdomyolysis Statin Drugs Defective Drugs Diseases The consumer group Public Citizen has stated that the rate of reported kidney problems is approximately 75 times higher with Crestor than with all other drugs in the same class combined. According to its analysis, there have been 6.4 reports of acute kidney failure or kidney damage for every 1 million Crestor prescriptions filled. Crestor has been linked to numerous cases of Rhabdomyolysis, a rare muscle destroying disease. Crestor is in the popular family of cholesterol-lowering drugs called Statins. Several years ago Baycol, another popular statin drug, was banned for its link to Rhabdomyolysis. Crestor Side Effects were Evident Before it was Approved Crestor was approved by the FDA in August 2003, after a delay because of safety concerns. During FDA studies seven cases of the potentially fatal, muscle-destroying condition Rhabdomyolysis occurred. These studies also linked Crestor with cases of kidney abnormalities not seen with other Statins. The FDA decided to approve Crestor but at lower dosages. However, records from the FDA and health agencies in Canada and Britain show life-threatening side effects occur even at those lower doses. Rhabdomyolysis is a serious disorder that causes kidney damage resulting from toxic effects of the contents of muscle cells. Myoglobin is an iron-containing pigment found in the skeletal muscle. When the skeletal muscle is damaged, the Myoglobin is released into the bloodstream. It is filtered out of the bloodstream by the kidneys. Myoglobin may obstruct the structures of the kidney, causing damage such as acute tubular necrosis or kidney failure. If you or a loved one took Crestor and suffered side effects, please fill out the form at the right for a free lawsuit case evaluation by a qualified drug side effects attorney.
2 Crestor (Rosuvastatin) Chemical Composition Rosuvastatin chemical structure Rosuvastatin is a member of the drug class of statins, used to treat hypercholesterolemia and related conditions, and to prevent cardiovascular disease. It is currently being marketed by the pharmaceutical company AstraZeneca as Crestor. Presentation Rosuvastatin is available as Crestor in tablet form (10, 20, or 40 mg) for oral administration. Tablets are pink, round or oval (40 mg), biconvex, film-coated, and imprinted with "ZD4522" and tablet strength. Japanese approval is in the dose range of 2.5 mg to 20 mg; therefore, smaller dose tablet forms might also be available outside the United States. Note that 97% of worldwide sales have been at or below the 20 mg dose. Mechanism of action Rosuvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, having a mechanism of action similar to other statins. Indications and regulation Rosuvastatin is indicated for the treatment of elevated LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia). As of 2004, rosuvastatin had been approved in 67 countries and launched in 56. Approval in the United States by the FDA came on August 12, 2003.
3 Marketing & Competition The drug was billed as a super-statin during its clinical development, claimed to offer a high potency and improved cholesterol reduction compared to rivals in the class. Currently the main competition for Crestor is Vytorin by Merck & Co. (a combination of simvastatin (Zocor) and ezetimibe (Zetia)); unfortunately, there are no published studies showing which of the two drugs is more effective. First launched in 2003, sales were $129 million and $908 million in 2003 and 2004, respectively, with a total patient treatment population of >4 million by the end of Debate & Criticisms Several months after its introduction in Europe, Richard Horton, the editor of the medical journal The Lancet, criticised the way Crestor had been introduced. "AstraZeneca's tactics in marketing its cholesterol-lowering drug, rosuvastatin, raise disturbing questions about how drugs enter clinical practice and what measures exist to protect patients from inadequately investigated medicines," according to his editorial. The Lancet's editorial position is that the data for Crestor s superiority relies too much on extrapolation from the lipid profile data and too little on hard clinical endpoints, which are available for other statins. The manufacturer responded by claiming that few drugs had been tested so successfully on so many patients. In correspondence published in The Lancet, AstraZeneca's CEO Sir Tom McKillop called the editorial "flawed and incorrect" and slammed the journal for making "such an outrageous critique of a serious, well-studied medicine." In 2004, the consumer interest organisation Public Citizen filed a Citizen's Petition with the FDA asking that Crestor be withdrawn from the US market. In 2005, the FDA, after a 14 month review of the specifics for each of the 35 individuals cited in the petition, formally denied this petition as not demonstrating any basis for additional concerns about rosuvastatin. Thirty two of the individuals had taken rosuvastatin at some time but the evidence was that their problems were most strongly related to other existing health issues and 3 of the 35 individuals had never taken rosuvastatin. Myopathy Some doctors have been hesitant to prescribe rosuvastatin because studies have suggested that this drug has a higher incidence of rhabdomyolysis (a severe undesired side effect) than other statins; this negative impact on sales performance has been much more pronounced in the United States than in other countries. The FDA has indicated that "it does not appear that the risk [of rhabdomyolysis] is greater with Crestor than with other marketed statins", but has mandated that a warning about this side effect, as well as a kidney toxicity warning, be added to the product label. [ Regarding myopathy and potential rhabdomyolysis, recent reviews of published data on all statins marked in the US, and reviewed by the FDA, have found that marked rises in the serum levels of muscle CK enzymes to 10 times normal or greater, the hallmark of serious
4 muscle problems, remain very rare, 1:10,000 to 1:20,000 individuals. Cerivastatin was an exception with a higher myopathy response. For the statins still on the market in the US, reported toxicity levels has been highest for pravastatin, simvastatin next, atorvastatin next and rosuvastatin the lowest at similar milligram doses. Yet the efficacy of these agents to change blood LDLipoproteins levels, at the same milligram doses, is the exact opposite. So, from the standpoint of the rare but serious muscle toxicity events, rosuvastatin, as of mid has turned out to have the best therapeutic index of the currently available statins. Renal Effects Regarding kidney function effects, recent reviews of published trial data, focusing on renal function, on placebo vs. statin, and tracking renal function over time have shown a small but distinct effect of statins to lessen renal dysfunction, when added to treatment (compared to placebo), and to slow the progression of further renal function decline over time. All the statins have a somewhat dose related response to increase urine protein levels, rosuvastatin the strongest association. Because increased urine protein has long been relied upon as a warning sign of renal glomerular dysfunction, this increase on statin treatment had been feared to indicate a negative effect on renal function. However, all current evidence is that the increase in urinary protein is from the renal tubular cells, not the glomeruli, and is due to cholesterol synthesis inhibition the tubular cells but is not associated with any decline in renal function. Instead, as mentioned above, clinical experience is that renal function, especially in those with partial renal failure, actually improves slightly and the rate of further decline decreases compared with those in the same trials who were randomized to the placebo agent. Comments, Changing Beliefs In general, experience with human responses to the statin agents has increasingly and dramatically driven a shift of conclusions toward the concept that much of common adult cholesterol production and blood transport behavior is unhealthy, even though cholesterol is an essential component of all human cell membranes. Though it is normal (i.e. common) for blood concentrations of LDLipoproteins to progressively rise with age as people get older, this is also strongly associated with development and progression of atherosclerotic plaque, typically not present as children under age 5 when cholesterol content of the blood LDLipoproteins is typically about 35 mg/dl. Scientists, physicians and the public continue to debate the issues and their varied and strongly held beliefs, yet clinical experience and research tracking of the benefits vs. risks has increasingly demonstrated realities contrary to the understanding and beliefs of many. Source Wikipedia.org
5 FDA Patient Information Sheet Crestor (Rosuvastatin Calcium) This is a summary of the most important information about Crestor. For details, talk to your healthcare professional. FDA ALERT: Rhabdomyolysis (serious muscle damage) has been reported in patients taking Crestor as well as other statin drugs. To date, it does not appear that the risk is greater with Crestor than with other marketed statins. However, the labeling for Crestor is being revised to highlight important information on the safe use of Crestor to reduce the risk for serious muscle damage, especially at the highest approved dose of 40 mg. In addition, a study has found that the amount of drug in the blood of a diverse group of Asian patients taking Crestor was two times higher than for Caucasians patients in the study. Therefore, the labeling for Crestor will now recommend a lower starting dose of 5 mg for Asian patients. Kidney failure of various types has also been reported in patients treated with Crestor as well as other statins. FDA has determined that there is not enough evidence to conclude that kidney damage is a direct result of Crestor therapy. If you are currently taking Crestor or any statin and develop signs and symptoms of muscle pain and weakness, fever, dark urine, nausea or vomiting, you should contact your healthcare professional right away. This information reflects FDA s preliminary analysis of data concerning this drug. FDA is considering, but has not reached a final conclusion about, this information. FDA intends to update this sheet when additional information or analyses become available. What Is Crestor? Crestor is a medicine that lowers "bad" cholesterol and triglycerides and raises "good" cholesterol in the blood. Crestor is part of a treatment program that should also include a lowfat diet and exercise. Who Should Not Take Crestor? Do not take Crestor if you: Have liver problems or have persistently high liver enzymes Are pregnant or planning to become pregnant. Crestor may harm your unborn baby. If you get pregnant, stop Crestor and call your healthcare professional right away. Are breast-feeding. It is not known if Crestor can pass into your milk, and if it can harm your baby. You should choose to either take Crestor or breastfeed, but not both. Are allergic to Crestor or any of its ingredients Crestor has not been studied in children.
6 What Are The Risks? Crestor may cause rare, but serious, side effects including: Muscle damage. Crestor can cause serious muscle damage that can lead to kidney damage. The risk of muscle damage may be increased by taking certain drugs. Crestor should be used with caution if you have kidney problems, advanced age, and hypothyroidism because you are at a greater risk of muscle damage. Tell your healthcare professional if you develop unexplained muscle pain, tenderness, or weakness while on Crestor, particularly if accompanied by malaise or fever. Liver damage. Crestor can cause liver damage like other lipid lowering medicines. This risk may be increased when Crestor is used with certain medicines. Your healthcare professional may do blood tests to check your liver before you start taking Crestor, and while you take it. Crestor should be used with caution if you have a history of liver disease or drink substantial amounts of alcohol. Other side effects include muscle pain, constipation, weakness, abdominal pain, and nausea What Should I Tell My Healthcare Professional? Before starting Crestor, tell your healthcare professional about all your medical conditions, including if you: Are pregnant or planning to become pregnant Are breast-feeding Have liver problems Have kidney problems Drink alcohol Are There Any Interactions With Drugs Or Foods? Tell your healthcare professional about all the medicines you take, including prescription and over the counter drugs, and supplements. Crestor and certain medicines may interact with each other causing serious side effects. Crestor and other medicines may affect each other, causing serious side effects. Especially tell your healthcare professional if you take: Cyclosporine (Gengraf, Neoral, Sandimmune) Warfarin (Coumadin) Gemfibrozil (Lopid) Drugs that may decrease the levels or activity of your body s own steroid hormones. These drugs include ketoconazole (Nizoral), spironolactone (Aldactone), and cimetidine (Tagamet) Aluminum and magnesium hydroxide combination antacids (for example, Maalox)
7 How do I take Crestor? You should be placed on a standard lipid-lowering diet and an exercise routine before receiving Crestor and should continue these during treatment. Crestor can be taken as a single dose at any time of day, with or without food. The dose range for Crestor is 5 to 40 mg once daily. You should start on the lowest possible dose, and never start with 40 mg. After starting or changing your dose of Crestor, your lipid levels should be checked within 2 to 4 weeks and your dose adjusted as needed. Crestor FDA Approved 2003 Patient Information Sheet Revised 03/2005 If you or a loved one has been injured by Crestor, Parker & Waichman, LLP will evaluate your case for free. Click here for a free, no obligation, case evaluation.
Crestor and thyroid problems
Recently it has been observed that many people on statins have been referred for special radioiodine studies because they have been found to have low to no thyroid stimulating hormone (TSH) in their blood
More informationDiseases & Conditions
http://my.clevelandclinic.org Diseases & Conditions About Cholesterol-Lowering Drugs Some people have a genetic predisposition to high blood cholesterol levels. These people may need drug therapy in addition
More informationCROSUVA CONSUMER MEDICINE INFORMATION
(Rosuvastatin film-coated tablets 5, 10, 20 and 40 mg) Rosuvastatin calcium Consumer Medicine Information What is in this leaflet This leaflet answers some of the common questions people ask about. It
More informationROSUVASTATIN RBX Tablets Rosuvastatin calcium
Tablets Rosuvastatin calcium Consumer Medicine Information What is in this leaflet This leaflet answers some of the common questions people ask about. It does not contain all the information that is known
More informationCAVSTAT contains the active ingredient rosuvastatin calcium
CAVSTAT contains the active ingredient rosuvastatin calcium CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some of the common questions people ask about CAVSTAT. It does not
More informationCholesterol. Medicines To Help You
Medicines To Help You Cholesterol Use this guide to help you talk to your doctor, pharmacist, or nurse about your cholesterol medicines. The guide lists all of the FDA-approved products now available to
More informationROSUVASTATIN APOTEX Rosuvastatin calcium
ROSUVASTATIN APOTEX Rosuvastatin calcium Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet This leaflet answers some common questions about this
More informationCRESTOR rosuvastatin calcium tablets
PART III CONSUMER INFORMATION CRESTOR rosuvastatin calcium tablets This leaflet is part of a "Product Monograph" published when CRESTOR was approved for sale in Canada and is designed specifically for
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET CRESTOVAS (ROSUVASTATIN 5MG, 10MG, 20MG & 40MG, TABLETS USP) Please read this leaflet carefully before you start to take your medicine. It contains important information. Keep
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION LIPIDIL EZ. fenofibrate, NanoCrystal formulation tablets
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION LIPIDIL EZ fenofibrate, NanoCrystal formulation tablets Read this carefully before you start taking LIPIDIL EZ and each
More informationFull prescribing information is available to doctors and pharmacists on request.
INFORMATION FOR THE CONSUMER Full prescribing information is available to doctors and pharmacists on request. Sandoz Fenofibrate E reduces levels of low density cholesterol (LDL-C or bad cholesterol),
More informationRosuvastatin Sandoz WHAT IS IN THIS LEAFLET BEFORE YOU TAKE ROSUVASTATIN SANDOZ WHAT ROSUVASTATIN SANDOZ IS USED FOR
Rosuvastatin calcium film coated tablet Consumer Medicine Information WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Rosuvastatin It does not contain all the available information.
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION ORILISSA. elagolix (as elagolix sodium) tablets
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION ORILISSA elagolix (as elagolix sodium) tablets Read this carefully before you start taking ORILISSA and each time you
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Rosuvastatin 5 mg Film-coated Tablets Rosuvastatin 10 mg Film-coated Tablets Rosuvastatin 20 mg Film-coated Tablets Rosuvastatin 40 mg Film-coated Tablets rosuvastatin
More informationElements for a Public Summary
Rosuvastatin Stada 5 mg film-coated tablets Rosuvastatin Stada 10 mg film-coated tablets Rosuvastatin Stada 20 mg film-coated tablets Rosuvastatin Stada 40 mg film-coated tablets 25.8.2014, V1.1 PUBLIC
More informationPATIENT INFORMATION. Medicine To Treat: C ardiac Diseases. Lipid-Lowering Medicines. Statins Fibrates Fat Binding Agents Nicotinic Acid Group
PATIENT INFORMATION Medicine To Treat: C ardiac Diseases Lipid-Lowering Medicines Statins Fibrates Fat Binding Agents Nicotinic Acid Group ABOUT YOUR MEDICINE Your doctor has just prescribed for you: Medicine
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr SIMVASTATIN 5 Pr SIMVASTATIN 10 Pr SIMVASTATIN 20 Pr SIMVASTATIN 40 Pr SIMVASTATIN 80 Simvastatin Tablets, USP This leaflet is part III of a three-part Product Monograph
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION ROSUVASTATIN-5 ROSUVASTATIN-10 ROSUVASTATIN-20 ROSUVASTATIN-40 Rosuvastatin Calcium Tablets This leaflet is part of a oduct Monograph published when ROSUVASTATIN was approved
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More information3 generations of ADPKD. 1 long-awaited treatment.
3 generations of ADPKD. 1 long-awaited treatment. HOPE is finally here now that treatment is available for people with autosomal dominant polycystic kidney disease (ADPKD). JYNARQUE is proven to slow kidney
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. ZEPATIER 50 mg of elbasvir and 100 mg of grazoprevir
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION ZEPATIER 50 mg of elbasvir and 100 mg of grazoprevir Read this carefully before you start taking ZEPATIER and each time
More informationPravastatin conversion to atorvastatin
P ford residence southampton, ny Pravastatin conversion to atorvastatin Pravastatin official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationPackage leaflet: Information for the user. Fluvastatin
Package leaflet: Information for the user Lescol XL 80 mg prolonged-release tablets Fluvastatin Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION Pr CADUET (amlodipine besylate and atorvastatin calcium tablets) This leaflet is Part III of a three-part "Product Monograph" published when CADUET was approved for sale
More informationClinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:
Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationScientific conclusions
Annex II Scientific conclusions and grounds for amendment of the summary of product characteristics, labelling and package leaflet presented by the European Medicines Agency 24 Scientific conclusions Overall
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels
More informationClinical Policy: Ezetimibe (Zetia) Reference Number: CP.PMN.78 Effective Date: Last Review Date: 02.19
Clinical Policy: (Zetia) Reference Number: CP.PMN.78 Effective Date: 02.01.17 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCHOLESTAGEL 625 mg Genzyme
CHOLESTAGEL 625 mg Genzyme 1. NAME OF THE MEDICINAL PRODUCT Cholestagel 625 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 625 mg colesevelam hydrochloride (hereafter
More informationLochol XL 80 mg Prolonged-release Tablets
Package leaflet: Information for the user Lochol XL 80 mg Prolonged-release Tablets Fluvastatin Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Rosuvastatin 5 mg Film-coated Tablets Rosuvastatin 10 mg Film-coated Tablets Rosuvastatin 20 mg Film-coated Tablets Rosuvastatin 40 mg Film-coated Tablets rosuvastatin
More informationMEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets
FDA-Approved Medication Guide MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets Savella is not used to treat depression, but it acts like medicines that are used to treat depression (antidepressants)
More informationMEDICATION GUIDE XIGDUO XR (ZIG- DO- OH X- R) (dapagliflozin and metformin HCL extended-release) Tablets
XIGDUO XR (dapagliflozin and metformin HCl extended-release) tablets 5 MEDICATION GUIDE XIGDUO XR (ZIG- DO- OH X- R) (dapagliflozin and metformin HCL extended-release) Tablets What is the most important
More informationGetting started with PROMACTA (eltrombopag)
Getting started with PROMACTA (eltrombopag) Indications PROMACTA is a prescription medicine used to treat adults and children 1 year and older with low blood platelet counts due to chronic immune (idiopathic)
More informationPackage leaflet: Information for the user. Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium)
PACKAGE LEAFLET Package leaflet: Information for the user Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium) Read all of this leaflet carefully before you start taking this medicine because
More informationEzetimib Stada 10 mg tablets
Ezetimib Stada 10 mg tablets 13.7.2016, Version V1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Ezetimib Stada 10 mg tablets VI.2.1 Overview of disease epidemiology Having
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationCRESTOR 10 mg, 20 mg, 40 mg Film Coated Tablets
CRESTOR 10 mg, 20 mg, 40 mg Film Coated Tablets COMPOSITION Each film coated tablet contains 10 mg, 20 mg, or 40 mg of rosuvastatin as rosuvastatin calcium. PHARMACEUTICAL FORM Film-coated tablet Round,
More informationJuly 2011 Medical Update Information
July 2011 Medical Update Information Simvastatin (Zocor) new FDA restrictions FDA statement June 2011 Based on the SEARCH 7 year trial in patients who were considered stable after have had a heart attack.
More informationYou have other factors that increase your risk of having a heart attack, stroke or related health problems.
Package leaflet: information for the patient Crestor 5 mg film-coated tablets Crestor 10 mg film-coated tablets Crestor 20 mg film-coated tablets Crestor 40 mg film-coated tablets rosuvastatin Read all
More informationModule 1.3 Product Information Version: Module Package Leaflet Replaces: Package leaflet: Information for the user
Module 1.3 Product Information Version: 2018-04-30 Module 1.3.1 Package Leaflet Replaces: 2017-10-13 Package leaflet: Information for the user Rosuvastatine Apotex 5 mg filmomhulde tabletten Rosuvastatine
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.05 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationThis document was created on 07 January 2005 and has been printed from
1 Spontaneous Adverse Event Reporting Information Introduction This document provides information regarding spontaneous adverse event reports received concerning patients taking rosuvastatin, which relates
More informationPATIENT INFORMATION LEAFLET SIMVACOR RANGE
SCHEDULING STATUS: S4 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: SIMVACOR 10 mg (Each film coated tablet contains simvastatin 10 mg) SIMVACOR 20 mg (Each film coated tablet contains simvastatin
More informationPackage leaflet: Information for the user. Ezetimibe STADA 10 mg, tabletten. Ezetimibe
Package leaflet: Information for the user Ezetimibe STADA 10 mg, tabletten Ezetimibe Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationATORIS 10, 20, 40 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER ATORIS 10, 20, 40 mg film-coated tablets ATORVASTATIN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationVI.2 Elements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology This medicine is used to lower levels of total cholesterol, LDL cholesterol ( bad cholesterol), and fatty substances called triglycerides
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Ezetimibe/simvastatin is used to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD). CHD occurs
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationsrmp Atorvastatin Medical Valley
srmp Atorvastatin Medical Valley VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology This product is indicated for the lowering of cholesterol blood levels and the prevention of
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationSimvastatin 40 mg equivalent
Simvastatin 40 mg equivalent medications equivalent to Simvastatin is available on the Drugs.com website. Simvastatin (Zocor ): 10 mg : Equivalent Dosages - 3: Atorvastatin (Lipitor. 40 mg : Equivalent
More informationPravat 40 mg tablets. Pravastatin sodium
Package leaflet: Information for the patient Pravat 10 mg tablets Pravat 20 mg tablets Pravat 40 mg tablets Pravastatin sodium Read all of this leaflet carefully before you start taking this medicine because
More informationStudy 1 ( ) Pivotal Phase 3 Long-Term Safety Study Top-Line Results
Study 1 (1002-040) Pivotal Phase 3 Long-Term Safety Study Top-Line Results May 2, 2018 1 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE Safe Harbor Forward-Looking Statements These
More informationReaders Digest 11/18/04 10:01 AM Page 1 Lowering cholesterol THE STELLAR STUDY Bad cholesterol (LDL-C) lowering effect isn t a game. It s vital
224174-Readers Digest 11/18/04 10:01 AM Page 1 Lowering cholesterol THE STELLAR STUDY Bad cholesterol (LDL-C) lowering effect isn t a game. It s vital to know not all drugs are the same. Your results may
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
Ezetimibe-simvastatin 10-80 mg oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationCRESTOR 10 mg, 20 mg, 40 mg ASTRAZENECA
10-14 rosuvastatin calcium Film coated tablets Composition Each tablet contains 5 mg, 10 mg, 20 mg, or 40 mg of rosuvastatin (as calcium salt). Also contains glycerol. Pharmaceutical form Film-coated tablet.
More informationElements for a Public Summary. Overview of disease epidemiology. Cardiovascular Events
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Cardiovascular Events Each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in
More informationPackage leaflet: Information for the patient. Atorvastatin Krka 40 mg film-coated tablets. Atorvastatin
PACKAGE LEAFLET Package leaflet: Information for the patient Atorvastatin Krka 10 mg film-coated tablets Atorvastatin Krka 20 mg film-coated tablets Atorvastatin Krka 40 mg film-coated tablets Atorvastatin
More informationTREATMENT PLAN WORKBOOK
TREATMENT PLAN WORKBOOK Keep track of everything related to your diagnosis and treatment Please see accompanying full Prescribing Information and Important Safety Information on page 15. Please see accompanying
More informationP A C K A G E L E A F L E T INFORMATION FOR THE USER. Simvastatin Genericon 20 mg - film-coated tablets
P A C K A G E L E A F L E T INFORMATION FOR THE USER Simvastatin Genericon 20 mg - film-coated tablets Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may
More informationElements for a Public Summary
VI.2 Elements for a Public Summary / / 10 mg/10 mg tablets / / 10 mg/20 mg tablets / / 10 mg/40 mg tablets / / 10 mg/80 mg tablets VI.2.1 Overview of disease epidemiology Prevention of cardiovascular events
More informationPatient Information SIVEXTRO (sih-vex-tro) (tedizolid phosphate) tablets
What you need to know about SIVEXTRO Patient Information SIVEXTRO (sih-vex-tro) (tedizolid phosphate) tablets Before you take this medicine, be sure you understand what it is for and how to take it safely.
More informationIMPORTANT: PLEASE READ What GD-amlodipine/atorvastatin does: PART III: CONSUMER INFORMATION Pr GD-amlodipine/atorvastatin
PART III: CONSUMER INFORMATION Pr GD-amlodipine/atorvastatin (amlodipine besylate and atorvastatin calcium tablets) This leaflet is Part III of a three-part "Product Monograph" published when GDamlodipine/atorvastatin
More informationRosuvastatin 5 mg, 10 mg and 20 mg Tablet
Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Description is a preparation of Rosuvastatin. Rosuvastatin is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to
More informationYour B.E.D. Discussion Guide
Your B.E.D. Discussion Guide Binge Eating Disorder (B.E.D.) is a real medical disorder. Mark any symptoms you ve been experiencing within the last 3 months. Share your results with your doctor to help
More informationMEDICATION GUIDE Abacavir, Lamivudine and Zidovudine Tablets (a-bak-a-vir, la-miv-ue-deen, zye-doe-vue-deen)
MEDICATION GUIDE Abacavir, Lamivudine and Zidovudine Tablets (a-bak-a-vir, la-miv-ue-deen, zye-doe-vue-deen) What is the most important information I should know about abacavir, lamivudine and zidovudine
More informationEzetimibe Sandoz Ezetimibe 10 mg tablet
Consumer Medicine Information Ezetimibe Sandoz Ezetimibe 10 mg tablet WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Ezetimibe Sandoz. It does not contain all the available information.
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Rosuva 5 mg Film-Coated Tablets Rosuva 10 mg Film-Coated Tablets Rosuva 20 mg Film-Coated Tablets Rosuva 40 mg Film-Coated Tablets Rosuvastatin Read all of
More informationMEDICATION GUIDE JANTOVEN (JAN-to-ven) Tablets (Warfarin Sodium Tablets, USP)
MEDICATION GUIDE JANTOVEN (JAN-to-ven) Tablets (Warfarin Sodium Tablets, USP) Read this Medication Guide before you start taking JANTOVEN (Warfarin Sodium Tablets, USP) and each time you get a refill.
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationIt is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
More informationPatient Information. For patients with diabetes, if you are taking TWYNSTA you should not take aliskiren.
Patient Information TWYNSTA (TWIN-stah) (telmisartan/amlodipine) Tablets Read this Patient Information before you start taking TWYNSTA tablets and each time you get a refill. There may be new information.
More informationPATIENT INFORMATION Metformin Hydrochloride Extended-Release Tablets (met-for-min HYE-droe-KLOR-ide) Rx only
PATIENT INFORMATION Metformin Hydrochloride Extended-Release Tablets (met-for-min HYE-droe-KLOR-ide) Rx only What is the most important information I should know about metformin hydrochloride extended-release
More informationQuestions to ask your Doctor
Questions to ask your Doctor What is my current blood pressure? What are my target blood pressure numbers? What blood pressure medication(s) am I currently taking? How is this drug different from what
More informationPharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More informationInvestor Presentation
Investor Presentation May 1, 2018 Albert Friesen Chair, President & CEO James Kinley CFO Forward Looking Statement This presentation is for informational purposes only and should not be considered as an
More informationMEDICATION GUIDE. for the long-term treatment of conditions where your stomach makes too much acid.
MEDICATION GUIDE Pantoprazole Sodium Delayed-Release Tablets pan toe pra zole soe dee um Read this Medication Guide before you start taking pantoprazole sodium delayed-release tablets and each time you
More informationElements for a Public Summary. PhV Page 54/143
VI.2 Elements for a Public Summary PhV-20141675 Page 54/143 VI.2.1 Overview of disease epidemiology Hypercholesterolaemia Hypercholesterolemia (high levels of cholesterol in the blood) is usually discovered
More informationMedication Guide SEGLUROMET (seg-lur-oh-met) (ertugliflozin and metformin hydrochloride) tablets, for oral use
Medication Guide SEGLUROMET (seg-lur-oh-met) (ertugliflozin and metformin hydrochloride) tablets, for oral use Read this Medication Guide carefully before you start taking SEGLUROMET and each time you
More informationMEDICATION GUIDE ELIQUIS (ELL eh kwiss) (apixaban) tablets
MEDICATION GUIDE ELIQUIS (ELL eh kwiss) (apixaban) tablets What is the most important information I should know about ELIQUIS? For people taking ELIQUIS for atrial fibrillation: People with atrial fibrillation
More informationJYNARQUE REMS (RISK EVALUATION AND MITIGATION STRATEGY) PATIENT GUIDE
JYNARQUE REMS (RISK EVALUATION AND MITIGATION STRATEGY) PATIENT GUIDE Patients: Your healthcare provider will go over this patient guide with you. It is important to ask any questions you may have. Keep
More informationCholesterol targets and therapy Thomas C. Andrews, MD, FACC
Cholesterol targets and therapy Thomas C. Andrews, MD, FACC 2 Statins in secondary prevention Still first line therapy! First line therapy: high intensity statin Dose individualized based on baseline LDL
More informationWhat should I discuss with my health care provider before taking eltrombopag?
1 of 6 6/10/2016 3:57 PM Generic Name: eltrombopag (el TROM boe pag) Brand Name: Promacta What is eltrombopag? Eltrombopag is a man-made form of a protein that increases production of platelets (blood-clotting
More informationReference ID:
MEDICATION GUIDE NEURONTIN (Neu rŏn' tĭn) (Gabapentin) Capsules, Tablets, and Oral Solution Read the Medication Guide before you start taking NEURONTIN and each time you get a refill. There may be new
More informationPage 1 of 5 VERZENIO abemaciclib tablet Eli Lilly and Company AddendaIndex Summary View All Sections HIGHLIGHTS OF PRESCRIBING INFORMATION FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE
More informationDoctor Discussion Guide
Talking to your healthcare provider about LONSURF (trifluridine and tipiracil) tablets If you have colon or rectal cancer that has spread to other parts of your body and have previously been treated with
More informationPackage leaflet: Information for the user. Resolor 1 mg film-coated tablets Resolor 2 mg film-coated tablets prucalopride
Package leaflet: Information for the user Resolor 1 mg film-coated tablets Resolor 2 mg film-coated tablets prucalopride Read all of this leaflet carefully before you start taking this medicine because
More informationCrestor vs lipitor for women
Crestor vs lipitor for women If you've already found that your cholesterol levels are getting dangerously out of sync, you can. American Heart Association: High Risk Factors and Coronary Heart Disease.,
More informationIf you have any concerns about taking this medicine, ask your doctor or pharmacist.
EZETROL ezetimibe 10 mg tablet What is in this leaflet This leaflet answers some common questions about EZETROL. It does not contain all the available information. It does not take the place of talking
More informationGLEEVEC PATIENT RESOURCES
GLEEVEC TALKING WITH YOUR DOCTOR ABOUT KIT+ GIST AND ITS TREATMENT When you have KIT-positive gastrointestinal stromal tumor (KIT+ GIST), you will likely have many questions and may, at times, feel overwhelmed
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin 250 mg Tablets sodium fusidate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More information